Pretargeted Radioimmunotherapy of Colorectal Cancer: A Phase I Study to Determine Dose-limiting Toxicity and Maximum Tolerated Dose of an Anti-CEACAM5 bsMAb-pretargeted 90Y-hapten-peptide.

Trial Profile

Pretargeted Radioimmunotherapy of Colorectal Cancer: A Phase I Study to Determine Dose-limiting Toxicity and Maximum Tolerated Dose of an Anti-CEACAM5 bsMAb-pretargeted 90Y-hapten-peptide.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Sep 2012

At a glance

  • Drugs TF 2 (Primary) ; Indium-111-IMP 288
  • Indications Colorectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Sep 2012 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 18 Jan 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top